MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha ® (evolocumab injection) for eligible ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...
NEW ORLEANS -- This weekend, catheter-based therapies have potentially practice-changing trial results expected at the American College of Cardiology (ACC) annual conference. Kicking off the opening ...
Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and high LDL but no heart disease, evolocumab reduced major adverse CV events compared ...
Hosted on MSN
Bristol Myers Squibb adding 3 medications on TrumpRx
EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from ...
Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results